登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603939 证券简称：益丰药房 公告编号：2025-106 债券代码：113682 债券简称：益丰转债 益丰大药房连锁股份有限公司 关于2022年限制性股票激励计划 ■ 一、本次限制性股票回购注销的决策与信息披露 1、2025年9月30日，公司召开的第五届董事会第二十二次会议审议通过了《关于回购注销2022年限制性 股票激励计划部分限制性股票的议案》，同意对因离职、降级或绩效不达标的5名激励对象的25,516股 股份进行回购并注销，湖南启元律师事务所出具了相应的法律意见书。具体内容详见公司于2025年10月 1日在法定信息披露媒体披露的《关于回购注销2022年限制性股票激励计划部分限制性股票的公告》 （2025-094）。 2、公司根据《上市公司股权激励管理办法》等相关规定就本次股份回购注销事项履行了通知债权人程 序，具体内容详见公司于2025年10月1日在法定信息披露媒体披露的《关于回购注销部分限制性股票通 知债权人的公告》（公告编号：2025-095）。截至申报期间届满之日，公司未收到任何债权人对此项议 案提出书面异议的情况，也未收到任何债权人 ...

11月20日，益丰药房跌1.17%，成交额8451.61万元。两融数据显示，当日益丰药房获融资买入额680.34 万元，融资偿还1098.78万元，融资净买入-418.43万元。截至11月20日，益丰药房融资融券余额合计 1.09亿元。 融资方面，益丰药房当日融资买入680.34万元。当前融资余额1.07亿元，占流通市值的0.37%，融资余 额超过近一年60%分位水平，处于较高位。 机构持仓方面，截止2025年9月30日，益丰药房十大流通股东中，香港中央结算有限公司位居第二大流 通股东，持股1.99亿股，相比上期减少3819.35万股。南方中证500ETF（510500）位居第七大流通股 东，持股881.27万股，相比上期减少17.31万股。交银新成长混合（519736）位居第八大流通股东，持股 845.41万股，为新进股东。中欧医疗健康混合A（003095）退出十大流通股东之列。 责任编辑：小浪快报 资料显示，益丰大药房连锁股份有限公司位于湖南省长沙市麓谷高新区金洲大道68号，成立日期2008年 6月20日，上市日期2015年2月17日，公司主营业务涉及药品、保健品、医疗器械以及与健康相关的日用 便利品等的 ...

Core Viewpoint - Yifeng Pharmacy (603939) announced a share reduction plan by senior management, indicating potential liquidity needs among executives [1] Group 1: Management Share Reduction - Vice Presidents Wang Yonghui and Xiao Zaixiang plan to reduce their holdings by a total of no more than 213,900 shares through centralized bidding [1] - As of now, Wang Yonghui holds 601,440 shares and Xiao Zaixiang holds 254,760 shares [1] Group 2: Previous Reductions - The controlling shareholder and three senior executives have already completed share reduction plans this year [1] - From August 5 to August 6, 2025, the controlling shareholder, Houxin Chuangtou, and its concerted parties reduced their holdings by 24,248,200 shares, accounting for 2.00% of the total share capital [1] - Executives Gao Youcheng and Yan Jun reduced their holdings by 50,400 shares and 22,900 shares respectively between February 24 and May 23, 2025 [1] - Vice President Zhang Zhaoxu reduced his holdings by 20,200 shares through centralized bidding on January 2, 2025 [1] Group 3: Share Price Range - The reduction prices for the aforementioned shareholders and executives ranged from 22 yuan to 25 yuan [1]

Core Points - The company is holding its first extraordinary general meeting of shareholders on November 28, 2025, to discuss several important resolutions [20][21] - The meeting will adopt a combination of on-site and online voting methods, utilizing the Shanghai Stock Exchange's online voting system [21][20] - Key agenda items include amendments to the company's articles of association and the management rules, as well as changes in the company's registered capital [9][11][10] Meeting Details - The meeting will take place at 15:30 on November 28, 2025, at the company's headquarters in Changsha, Hunan Province [21][6] - Shareholders must register by November 24, 2025, to attend the meeting, providing necessary identification and authorization documents [2][29] - The network voting will be available from 9:15 to 15:00 on the day of the meeting [21][6] Resolutions to be Discussed - Resolution 1 involves the abolition of the supervisory board, transferring its powers to the audit committee of the board of directors [9] - Resolution 2 pertains to the amendment of the company's registered capital, which has been adjusted following the repurchase and cancellation of restricted stocks [10] - Resolutions 3 to 7 include amendments to various management rules, such as the rules for shareholder meetings and investment management [13][14][15][17][18] Voting Procedures - Shareholders can vote either in person or online, but must choose one method to avoid duplicate voting [4][23] - The voting process will require shareholders to fill out ballots clearly, as any unclear or unmarked ballots will be considered abstentions [3][4] - The results of the voting will be announced after all resolutions have been voted on [4][8] Contact Information - Shareholders can contact the company for any inquiries regarding the meeting through specified email and phone contacts [31]

Core Viewpoint - The company, Dajiahui Kang, has provided information regarding the distribution of its subsidiaries' pharmacies in Hainan province, specifically in cities such as Haikou, Wenchang, Qionghai, and Ding'an [1] Company Summary - Dajiahui Kang operates two main subsidiaries: Hainan Dajiahui Kang Pharmacy Chain Co., Ltd. and Hainan Dajiahui Kang Hongchuntang Pharmacy Chain Co., Ltd. [1] - The pharmacies are primarily located in Haikou, Wenchang, Qionghai, and Ding'an, indicating a focused regional presence in Hainan [1]

Core Viewpoint - Yifeng Pharmacy achieved a net profit attributable to shareholders of 1.225 billion yuan (+10.27%) in Q1-Q3 2025, with a net operating cash flow of 2.267 billion yuan (-32.16%), indicating stable growth and improved profitability, aligning with expectations [1] Company Performance - The company has strategically adjusted its store expansion strategy in response to industry clearing, leveraging strong management capabilities to enhance its multi-tiered store network, including flagship stores, regional center stores, medium-sized community stores, and small community stores [1] - Yifeng Pharmacy is deepening its regional market presence through both the breadth and depth of its store network, which is expected to enhance brand penetration [1] Market Strategy - The company is actively exploring the potential for category structure adjustments to continuously tap into market demand, which is likely to maintain its leading profitability in the industry [1] - The company maintains a "Buy" rating, reflecting confidence in its ongoing strategic initiatives and market positioning [1]

Core Viewpoint - Yifeng Pharmacy (603939.SH) reported a year-on-year increase in revenue and net profit for Q3 2025, indicating positive financial performance and growth potential in the pharmaceutical retail sector [1] Financial Performance - The company's operating revenue for Q3 2025 reached 5.564 billion yuan, representing a year-on-year increase of 1.97% [1] - The net profit attributable to shareholders of the listed company was 345 million yuan, showing a year-on-year increase of 10.14% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 331 million yuan, reflecting a year-on-year increase of 8.08% [1]

Core Points - The company has provided a guarantee for its wholly-owned subsidiary, Jiangsu Yifeng, to support its application for comprehensive credit from financial institutions [2][3] - The total amount of the guarantee provided by the company does not exceed 3.09 billion yuan, which is within the approved limit from the annual shareholders' meeting [3][5] - The guarantee is intended to meet the operational and business development funding needs of the company and its subsidiary, ensuring smooth business operations [5] Summary by Sections Guarantee Details - The company signed a maximum guarantee contract with financial institutions in September 2025, providing joint liability guarantees for Jiangsu Yifeng's credit application [2] - The specific guarantee amount is 250 million yuan, covering various financial obligations including principal, interest, penalties, and related costs [3] Internal Decision-Making Process - The board of directors approved the guarantee proposal during meetings held on April 28, 2025, and May 29, 2025 [3] Financial Health of the Subsidiary - Jiangsu Yifeng is described as having good profitability and the ability to repay debts, with financial risks being manageable within the company [5] Board's Opinion - The board believes that providing the guarantee is a reasonable estimate based on business development needs and financial capabilities, aligning with the company's overall strategic goals [5] Cumulative Guarantee Situation - As of the announcement date, the total external guarantees provided by the company and its subsidiaries amount to 3.315 billion yuan, representing 30.91% of the latest audited net assets [5]

Core Insights - Yifeng Pharmacy's stock price remained unchanged on October 22, with a trading volume of 129 million yuan, indicating stable market activity [1] - The company reported a financing net purchase of 980,700 yuan on the same day, reflecting a low financing balance compared to historical levels [1] - For the first half of 2025, Yifeng Pharmacy achieved a revenue of 11.722 billion yuan, a slight decrease of 0.35% year-on-year, while net profit increased by 10.32% to 880 million yuan [2] Financing and Margin Trading - On October 22, Yifeng Pharmacy had a financing buy amount of 9.0041 million yuan and a financing repayment of 8.0234 million yuan, resulting in a net financing purchase of 980,700 yuan [1] - The total financing and margin trading balance as of October 22 was 98.1041 million yuan, with the financing balance at 93.2032 million yuan, representing 0.31% of the circulating market value [1] - The company’s financing balance is currently below the 40th percentile of the past year, indicating a low level of leverage [1] Shareholder and Dividend Information - As of June 30, the number of shareholders increased by 7.70% to 21,600, while the average circulating shares per person decreased by 7.15% to 56,081 shares [2] - Since its A-share listing, Yifeng Pharmacy has distributed a total of 2.852 billion yuan in dividends, with 1.946 billion yuan distributed in the last three years [3] - The second-largest circulating shareholder is Hong Kong Central Clearing Limited, holding 237 million shares, a decrease of 35.3896 million shares from the previous period [3]

Core Points - The announcement pertains to the second unlock and listing of restricted stock under the 2022 Restricted Stock Incentive Plan of Yifeng Pharmacy Chain Co., Ltd [1][2] Group 1: Stock Incentive Plan Overview - The stock type being listed is for equity incentive shares, with a total of 196,838 shares available for trading [2] - The listing date for these shares is set for October 27, 2025 [2] Group 2: Implementation of the Incentive Plan - The incentive plan was approved during the board and supervisory meetings held on August 19, 2022, with independent opinions provided by independent directors [3] - The names and positions of the incentive recipients were publicly disclosed from August 20 to August 29, 2022, with no objections received [3][4] - The plan was further approved at the third extraordinary general meeting of shareholders on September 5, 2022 [4] Group 3: Unlocking Conditions and History - The first unlock of 216,668 shares was approved on October 14, 2024, for 32 recipients [4][5] - The second unlock of 196,838 shares was approved on September 30, 2025, for 29 recipients [5] Group 4: Legal Compliance and Conclusion - The law firm Hunan Qiyuan concluded that the conditions for the unlock and listing have been met, and all necessary approval procedures have been followed [7]